Loading
A phase 1/2 trial of REM-422 in salivary gland cancers, run by Remix Therapeutics, now recruiting.
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma is a phase 1/2 interventional study registered as NCT06118086 by Remix Therapeutics, with 125 participants planned, started 2023-12-20 and due to reach its primary completion in 2027-09-30. Interventions recorded: REM-422.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adenoid cystic carcinoma, Salivary gland cancers and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.
Shares Salivary gland cancers and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/